• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic innovation & regulatory science. >Drug Target Identification and Validation: Global Pharmaceutical Industry Experts on Challenges, Best Strategies, Innovative Precompetitive Collaboration Concepts, and Future Areas of Industry Precompetitive Research and Development
【24h】

Drug Target Identification and Validation: Global Pharmaceutical Industry Experts on Challenges, Best Strategies, Innovative Precompetitive Collaboration Concepts, and Future Areas of Industry Precompetitive Research and Development

机译：药物靶标的识别和验证：全球制药行业专家，就挑战，最佳策略，创新的竞争前合作概念以及行业竞争前研究与开发的未来领域

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Focused interviews were conducted with global pharmaceutical company representatives in order to derive a consistent view on drug target identification/validation challenges, collaborative strategies, and future developments in a precompetitive space. Analysis revealed translation into clinical utility as a major hurdle of novel drug target validation, originating from lack of biological understanding, irreproducibility of published results, and lack of valid animal models. Direct and close collaborations with academia are the preferred model to tackle basic research on novel drug targets in high-risk projects. Efforts to conduct target identification in large precompetitive consortia are acknowledged with some doubts about the pace of progress and data-sharing policies, while concept to extend the precompetitive space to target validation in phase II trials was curtailed to niche indications together with a revision of current intellectual property (IP) practice. Public-private partnerships in established areas are forecasted to increase. Novel emerging themes are toxicology data sharing, joint genetic patient data analysis, and reimbursement concepts.
机译：与全球制药公司代表进行了重点访谈，以便就在竞争前的空间中对药物靶标的识别/验证挑战，协作策略以及未来发展得出一致的看法。分析表明，转化为临床实用性是新型药物靶标验证的主要障碍，其起因是对生物学的了解不足，所发表结果的不可再现性以及缺乏有效的动物模型。与学术界的直接和密切合作是解决高风险项目中有关新型药物目标的基础研究的首选模型。人们对大型竞争前财团进行目标识别的努力表示认可，但对进展的步伐和数据共享政策存有疑虑，而将竞争前领域扩展到第二阶段试验中目标验证的概念被缩小为利基适应症，同时修订了当前版本。知识产权（IP）实践。预计已建立地区的公私伙伴关系将增加。新兴的主题是毒理学数据共享，联合遗传患者数据分析和报销概念。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号